Epithalon (Injectable)

01 What is Epithalon (Injectable)?

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is based on epithalamin, a peptide extract from the pineal gland, and has been studied in Russia for decades as an anti-ageing agent. The injectable form is the gold standard for delivery — bypassing any oral degradation concerns. The core claim is that Epithalon activates telomerase — the enzyme that lengthens telomeres (the protective caps on your chromosomes that shorten with age). Shortened telomeres are one of the hallmarks of ageing, and maintaining telomere length is associated with longer healthspan. If Epithalon genuinely activates telomerase in humans, it would be one of the most significant anti-ageing interventions available. The evidence base is unusual — extensive Russian clinical research that meets different methodological standards than Western pharma trials. Multiple studies show improved biomarkers, melatonin normalisation, and potential lifespan extension in animals. The Western scientific community remains cautiously interested but wants more rigorous replication.

02 How Does It Work?

Epithalon stimulates telomerase production in somatic cells by activating the hTERT gene (human telomerase reverse transcriptase). This is the catalytic component of telomerase that adds telomeric repeats (TTAGGG) to chromosome ends. Additionally, Epithalon appears to: 1. Regulate pineal gland function — normalising melatonin production (which declines with age). 2. Modulate gene expression in a pattern associated with cell rejuvenation. 3. Influence antioxidant enzyme activity. 4. Potentially regulate circadian rhythm through pineal mechanisms. The injectable form ensures 100% bioavailability compared to oral or sublingual delivery.

03 What Does The Research Say?

Russian studies (Khavinson lab): Multiple human studies showing telomerase activation, improved melatonin secretion, normalised immune function, and cardiovascular improvements in elderly subjects. One famous study showed 46% reduction in mortality over 12 years in a cohort receiving epithalamin/thymalin treatment. Telomerase: Cell culture studies confirm telomerase activation in human somatic cells (not cancer cells). Animal studies show lifespan extension. Limitations: Most studies are from one research group, published in Russian journals, with methodology that would not pass modern Western trial standards. Independent replication by Western labs is limited but beginning to emerge.

04 Reported Dosages

Subcutaneous injection: 5-10mg daily for 10-20 day cycles, repeated 2-3 times per year. Some protocols use 5mg twice daily for 10 days. Cycle-based approach — not continuous use. Reconstitute from lyophilised powder with bacteriostatic water. DISCLAIMER: Not approved by FDA, MHRA, or EMA. All dosing comes from Russian clinical research and practitioner experience. Quality of peptide source is critical — ensure third-party testing.

05 Side Effects & Risks

Reported side effects are minimal — mild injection site reactions, occasional headache. Russian clinical data suggests excellent tolerability over decades of use. Theoretical concern: telomerase activation in cancer cells could theoretically promote tumour growth. However, research suggests Epithalon selectively activates telomerase in somatic cells, not transformed cells. Still, prudent to avoid during active cancer or with strong cancer risk factors.

06 Legal Status